骨代谢标志物在多发性骨髓瘤中的临床应用

翟云芝; 张浩然

doi:10.13898/j.cnki.issn.1000-2200.2018.09.004

骨代谢标志物在多发性骨髓瘤中的临床应用

Clinical application of serum bone metabolic markers in multiple myeloma

摘要

摘要: 目的：探讨多发性骨髓瘤（MM）病人血清中Ⅰ型前胶原氨基端延长肽（PINP）和Ⅰ型胶原蛋白羧基端β降解产物（β-CTX）水平及其临床意义。方法：利用电化学发光法来测定62例MM病人（MM组）和50名健康体检者（对照组）的血清PINP及β-CTX水平，比较不同临床分期的MM病人血清PINP和β-CTX水平的变化。结果：MM组病人血清PINP水平低于对照组（P<0.01），β-CTX水平高于对照组（P<0.01）。MM病人Ⅲ期β-CTX水平较Ⅰ期升高（P<0.05），Ⅱ期与Ⅰ期、Ⅲ期差异均无统计学意义（P>0.05），PINP水平在三期之间差异均无统计学意义（P>0.05）。结论：血清PINP和β-CTX水平可用于评价MM病人的骨破坏程度，β-CTX水平较PINP对MM病人的预后评价更为敏感。

Abstract: Objective:To investigate the levels of serum β-C-terminal telopeptide of typeⅠ collagen(β-CTX) and procollagenⅠN-terminal peptide(PINP) in patients with multiple myeloma(MM),and its clinical significance.Methods:The serum levels of β-CTX and PINP in 62 MM patients(MM group) and 50 healthy people(control group) were detected using the electrochemiluminescence immunoassay.The serum levels of β-CTX and PINP in different clinical stages patients with MM were compared between two groups.Results:The serum levels of PINP and β-CTX in MM groups were lower and higher than those in control group,respectively(P<0.01).The level of β-CTX in MM patients in stage Ⅲ was higher than that in stage Ⅰ (P<0.05),there was no statistical significance in the serum level of β-CTX between stage Ⅱ and stage Ⅰ or stage Ⅲ(P>0.05),and there was no statistical significance in the serum level of PINP among stage Ⅱ,stage Ⅰ and stage Ⅲ(P>0.05).Conclusions:The serum levels of PINP and β-CTX can be used to evaluate the degree of bone destruction in patients with MM.The level of β-CTX in evaluating the prognosis of patients with MM more sensitive than that of PINP.

HTML全文

参考文献(10)

施引文献

资源附件(0)